DDInter1510 DDInter1658
Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030.[A263206,A263211] Despite being approved since 1980, the exact mechanism of action is yet to be elucidated.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Praziquantel {u} (Compound) resembles {v} (Compound) Palonosetron
Praziquantel {u} (Compound) binds {v} (Gene) CYP3A5
Praziquantel {u} (Compound) upregulates {v} (Gene) PAK6
Praziquantel {u} (Compound) downregulates {v} (Gene) ATP6V1D
Praziquantel {u} (Compound) causes {v} (Side Effect) Decreased appetite
Praziquantel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Praziquantel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isavuconazonium
Praziquantel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Praziquantel {u} may lead to a major life threatening interaction when taken with {v} Lumacaftor
Praziquantel {u} may lead to a major life threatening interaction when taken with {v} Rifabutin
Praziquantel (Compound) resembles Palonosetron (Compound)
Praziquantel (Compound) binds CYP3A5 (Gene)
Praziquantel (Compound) upregulates PAK6 (Gene)
Praziquantel (Compound) downregulates ATP6V1D (Gene)
Praziquantel (Compound) causes Decreased appetite (Side Effect)
Praziquantel may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Praziquantel may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Praziquantel may lead to a major life threatening interaction when taken with Lumacaftor
Praziquantel may lead to a major life threatening interaction when taken with Rifabutin